BioKangtai is developing a recombinant subunit vaccine against Klebsiella pneumoniae, a WHO critical-priority “superbug” with rising carbapenem resistance and high mortality.
In pre-clinical studies, the vaccine candidate demonstrated >80 % protection in animal models while maintaining a strong safety profile. The candidate is designed for high-risk populations, including ICU and long-stay patients, post-surgical cases, older adults, infants, and individuals living with chronic conditions such as diabetes or chronic respiratory diseases like COPD.
BioKangtai's goal is to shift the paradigm from treatment to prevention, reduce reliance on last-line antibiotics, and strengthen the global response to antimicrobial resistance.
